Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: An analysis from the REVEAL study

Data from the prospective, observational REVEAL study of patients with polycythemia vera in the United States suggest that patients receiving hydroxyurea need active management to monitor for blood count control and potential intolerance to hydroxyurea. In the analysis, 32.3% of patients receiving hydroxyurea had dose adjustments, 23.7% had dose interruptions, and 18.6% discontinued the drug, with the most common reasons including adverse events/intolerance and lack of efficacy.